Investigating the potential of carbohydrate antibodies in cancer immunotherapy is an “under-attacked” area, Siamab Therapeutics Inc. CEO Jeff Behrens says, and he thinks his company now has important validation with an option-based collaboration with Boehringer Ingelheim GMBH.
The Newton, Mass. biotech’s technology focuses on therapeutics to target tumor-associated carbohydrate antigens (TACAs) in various types of solid tumors....








